Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Presidential Taskforce On Covid-19 Endorses Pfizer-BioNTtech Vaccine for 12+ Year Olds

11/30/2021 | 03:52am EST

Presidential taskforce on CoVID-19 has endorsed use of Pfeizer-BioNTech vaccine that covers for people as young as 12 years old and above.

A statement from the taskforce's chairperson, Health Minister Khumbize Kandodo Chiponda on Sunday, stressing that this extension is only for Pfeizer-BioNTech vaccine "for the time being, until further expert advice is available and announced regarding other vaccines".

The eligibility of the other vaccines available -- AstraZeneca (that require two doses after 14 weeks from the first jab) and the once off Johnson and Johnson -- is for those aged 18 years and above.

"Let me call upon all those that are eligible to access these services as soon as they are available to you," Kandodo Khumbize said in her statement on the situation of the Coronavirus pandemic in the country and review of rules and guidelines in the context of evolving regional and global.

She further said the Ministry of Health will soon publish guidelines on the use of Pfeizer-BioNTech CoVID-19 vaccine for those aged 12 years and over.

She reiterated that the positive uptake of the vaccines has demonstrated -- "even in our own country -- that the vaccine has been reducing the risk of developing severe disease, risk of hospitalization and deaths due to CoVID-19 while the other preventive measures help to prevent from contracting or passing on the virus, including the new variant".

"We have adequate stocks of COVID-19 vaccines in all our public, CHAM and ad hoc vaccination sites, and more are being procured," she said, while urging "all that are eligible go and get vaccinated before another wave comes upon us".

Last week, Blantyre District Health Office (DHO) issued an alert that following events in other parts of the Southern African Development Community (SADC) region, especially South Africa and Botswana, Blantyre residents are encouraged to be on high alert for an impending CoVID-19 fourth wave.

Issued by the DHO's Director of Health and Social Services, Dr. Gift Kawalazira on Friday, November 26), the statement alerts the general public that "from past experience, there is usually a four-week window period from the time South Africa records an increase in numbers of CoVID-19 cases to the time Malawi follows suit with Blantyre being the hardest hit".

"Blantyre residents are further reminded that the only effective way to protect oneself from CoViD-19 related serious illness or death is to get fully vaccinated against the disease.

"It is for this reason that Blantyre DHO would like to encourage all residents of 18 years and above that are not yet vaccinated to use the four week window period to get themselves vaccinated."

Dr. Kawalazira stressed that getting fully vaccinated gives people bodies time to build immunity against the CoVID-19 virus before it is too late while encouraging those that are due for their second dose of AstraZeneca vaccine to go for it.

So far, as of Sunday, November 28, a total of 1,407,233 vaccine doses have been administered in the country with cumulative figure of 807,376 having received their first dose of AstraZeneca and 325,364 their second jab while 274,493 have received Johnson and Johnson.

Over the past 24 hours of Sunday, 2,072 and 238 people have received first dose and second of AstraZeneca vaccine respectively whilst 168 received Johnson and Johnson -- giving a cumulative figure of 599,857 being fully vaccinated.

As of Sunday, eight new CoVID-19 cases were recorded that include two new recoveries and one new related death, who was not vaccinated. All new cases are locally transmitted -- six from Mangochi, one each from Lilongwe and Ntcheu Districts.

Cumulatively, Malawi has recorded 61,897 cases including 2,305 deaths at case fatality rate of 3.72%). Of these cases, 2,700 are imported infections and 59,197 are locally transmitted.

Cumulatively, 58,765 cases have now recovered at rate of 95% while 232 were lost to follow-up -- bringing the total number of active cases to 595.

There were no new admissions and no new discharges in the treatment units in the past 24 hours of Sunday currently, two active cases are hospitalised, one each in Blantyre and Mzimba North districts.

Kandodo Chiponda also informed the public that there is a new CoVID-19 strain circulating in some countries in the world which the World Health Organisation has identified as a variant of concern and given the name Omicron.

"Early evidence from South Africa suggests Omicron may be more transmissible, however research is still in progress," she said. "Emergence of new variants such as Omicron underlines why it is so important that we continue practising the required preventive measures.

"This particular strain is still in its infancy stage and as with any emerging developments to do with CoVID-19, we are closely watching and monitoring the evidence and the countries responses.

"The Government of Malawi will keep on advising the general public on any potential impact this new variant might cause. But learning from previous experience we are confident that we as a nation remain in a good position to minimise any potential negative impact provided everyone follows the recommended preventive measures."

Copyright Nyasa Times. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.11% 8744 Delayed Quote.0.85%
JOHNSON & JOHNSON -0.23% 164.87 Delayed Quote.-3.40%
All news about ASTRAZENECA PLC
01/21Investor's Net Asset Value Jumps 41% in 2021 As Low Interest Rate Environment Uplifts R..
01/20ASTRAZENECA : Deutsche Bank reaffirms its Buy rating
01/20EMA : In january 2022, prac concluded that transverse myelitis should be added to the prod..
01/20EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Sid..
01/19India's expert panel advises full approval for Covishield, Covaxin
01/19ASTRAZENECA : JP Morgan reiterates its Buy rating
01/19AstraZeneca PLC Announces Positive Results from the TOPAZ-1 Phase III Trial
01/19Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tr..
01/19AstraZeneca Says Liver Cancer Combination Therapy Improved Overall Survival in Late-Sta..
01/19AstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 096 M - -
Net income 2021 2 714 M - -
Net Debt 2021 24 816 M - -
P/E ratio 2021 57,3x
Yield 2021 2,37%
Capitalization 184 B 184 B -
EV / Sales 2021 5,78x
EV / Sales 2022 4,73x
Nbr of Employees 76 100
Free-Float -
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 118,62 $
Average target price 138,70 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325